XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1 - Nature of the Business
 9 Months Ended
Sep. 30, 2014
Disclosure Text Block [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.    Nature of the business:

Xenon Pharmaceuticals Inc. (the “Company”), incorporated in 1996 under the British Columbia Business Corporations Act and continued federally in 2000 under the Canada Business Corporation Act, is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own, and for larger market indications that it intends to partner with global pharmaceutical companies.

On October 1, 2014, the Company effected a 1 for 4.86 reverse share split of its common and Series A, B and E redeemable convertible preferred shares. All of the share numbers, share prices, and exercise prices in these financial statements have been adjusted, on a retroactive basis, to reflect this 1 for 4.86 reverse share split (note 11a(i)).

On November 10, 2014, the Company completed an initial public offering (“IPO”) of 4,600,000 of its common shares at a price to the public of $9.00 per share (note 11b). On November 10, 2014, the Company also completed a private placement, in which the Company issued and sold 495,000 of its common shares to an affiliate of Genentech, Inc. (“Genentech”) at a price of $9.00 per share (note 11b). Immediately prior to the closing of the IPO, all outstanding convertible preferred shares were converted into 7,725,924 common shares and 10,200 outstanding subscription rights were converted into 10,200 common shares (note 11a(ii)). Following the IPO, there were no preferred shares or subscription rights outstanding. The accompanying unaudited interim financial statements, including share and per share amounts, do not reflect the IPO.